Synthesis and SAR of 1,9-dihydro-9-hydroxypyrazolo[3,4-b]quinolin-4-ones as novel, selective c-Jun N-terminal kinase inhibitors

被引:25
作者
Liu, M [1 ]
Xin, ZL [1 ]
Clampit, JE [1 ]
Wang, SY [1 ]
Gum, RJ [1 ]
Haasch, DL [1 ]
Trevillyan, JM [1 ]
Abad-Zapatero, C [1 ]
Fry, EH [1 ]
Sham, HL [1 ]
Liu, G [1 ]
机构
[1] Abbott Labs, Metab Dis Res, Global Pharmaceut Res & Dev, Abbott Pk, IL 60064 USA
关键词
JNK; diabetes; obesity; pyrazoloquinolinones;
D O I
10.1016/j.bmcl.2006.02.046
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
A novel class of 1,9-dihydro-9-hydroxypyrazolo[3,4-b]quinolin-4-ones as c-Jun-N-terminal kinase (JNK) inhibitors is described. These compounds were synthesized via the condensation of 2-nitrobenzaldehydes and hydroxypyrazoles. The structure-activity relationships (SAR) and kinase selectivity profile of the inhibitors are also discussed. Compound 16 was identified as a potent JNK inhibitor with good cellular potency. (C) 2006 Elsevier Ltd. All rights reserved.
引用
收藏
页码:2590 / 2594
页数:5
相关论文
共 16 条
[1]   The c-Jun NH2-terminal kinase promotes insulin resistance during association with insulin receptor substrate-1 and phosphorylation of Ser307 [J].
Aguirre, V ;
Uchida, T ;
Yenush, L ;
Davis, R ;
White, MF .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2000, 275 (12) :9047-9054
[2]   The specificities of protein kinase inhibitors: an update [J].
Bain, J ;
McLauchlan, H ;
Elliott, M ;
Cohen, P .
BIOCHEMICAL JOURNAL, 2003, 371 :199-204
[3]   JNK: a new therapeutic target for diabetes [J].
Bennett, BL ;
Satoh, Y ;
Lewis, AJ .
CURRENT OPINION IN PHARMACOLOGY, 2003, 3 (04) :420-425
[4]   Design and synthesis of the first generation of novel potent, selective, and in vivo active (benzothiazol-2-yl)acetonitrile inhibitors of the c-Jun N-terminal kinase [J].
Gaillard, P ;
Jeanclaude-Etter, I ;
Ardissone, V ;
Arkinstall, S ;
Cambet, Y ;
Camps, M ;
Chabert, C ;
Church, D ;
Cirillo, R ;
Gretener, D ;
Halazy, S ;
Nichols, A ;
Szyndralewiez, C ;
Vitte, PA ;
Gotteland, JP .
JOURNAL OF MEDICINAL CHEMISTRY, 2005, 48 (14) :4596-4607
[5]   TRANSCRIPTION FACTOR ATF2 REGULATION BY THE JNK SIGNAL-TRANSDUCTION PATHWAY [J].
GUPTA, S ;
CAMPBELL, D ;
DERIJARD, B ;
DAVIS, RJ .
SCIENCE, 1995, 267 (5196) :389-393
[6]   A central role for JNK in obesity and insulin resistance [J].
Hirosumi, J ;
Tuncman, G ;
Chang, LF ;
Görgün, CZ ;
Uysal, KT ;
Maeda, K ;
Karin, M ;
Hotamisligil, GS .
NATURE, 2002, 420 (6913) :333-336
[7]   Synthesis of 3-ethoxycarbonyl-4-hydroxyquinoline N-oxides from the Baylis-Hillman adducts of o-nitrobenzaldehydes [J].
Kim, JN ;
Lee, KY ;
Kim, HS ;
Kim, TY .
ORGANIC LETTERS, 2000, 2 (03) :343-345
[8]   SUBSTITUENT INTERACTIONS IN ORTHO-SUBSTITUTED NITROBENZENES .4. [J].
LOUDON, JD ;
TENNANT, G .
JOURNAL OF THE CHEMICAL SOCIETY, 1962, (AUG) :3092-&
[9]  
LOUDON JD, 1960, J CHEM SOC, P3470, DOI 10.1039/jr9600003470
[10]   Targeting JNK for therapeutic benefit: From JuNK to gold? [J].
Manning, AM ;
Davis, RJ .
NATURE REVIEWS DRUG DISCOVERY, 2003, 2 (07) :554-565